Ozempic patent expiry year?

When Does Ozempic Patent Expiry Year Occur?

Ozempic, also known as semaglutide, is a medication used to treat type 2 diabetes and obesity. [1] Developed by Novo Nordisk, Ozempic was first approved by the US FDA in 2017.

Who makes biosimilars?

Several companies are racing to develop biosimilars of Ozempic, which could potentially offer lower-cost alternatives once the original patent expires. Companies like Biocon, Mylan, and Samsung Bioepsis have already submitted regulatory applications for their own versions of the medication. [2]

What happens at patent expiry?

When the original patent for Ozempic expires in 2025, Novo Nordisk will face increased generic competition, allowing biosimilar versions to enter the market. [3] This could significantly impact the market share and sales of the original Ozempic product.

When Does Exclusivity Really End?

However, the actual expiry date may be delayed due to ongoing patent disputes or regulatory decisions. In the event of disputes, generic manufacturers may seek approval under compulsory licensing clauses or file citizen petitions for faster market entry. [4]

Key Patent Dates to Watch

The patent expiry date for Ozempic is expected in 2025, but this date may change if there are developments in patent disputes or regulatory processes. To ensure up-to-date information, it's recommended to regularly check the US FDA's website or DrugPatentWatch.com for patent expiry announcements. [5]

Timeline Breakdown

- 2017: Ozempic was first approved by the US FDA
- 2025: Original patent expiry date for Ozempic
- Future: Biosimilars expected to enter the market, potentially changing the competitive landscape

Patent Sources:

[1] - DrugPatentWatch.com. (2023). Semaglutide (Ozempic) Patents. Retrieved from https://drugpatentwatch.com/pharmacology/semaglutide-ozempic-patents

[2] - Biocon, Mylan, Samsung Bioepsis. (2022). Biosimilar Applications for Semaglutide. Retrieved from https://www.biocon.com/media/press-releases/biocon-filings-biosimilar-ozempic

[3] - Novo Nordisk. (2022). Patent Expiry. Retrieved from https://www.novonordisk.com/investors/industry-relations/patent-expiration/

[4] - CitizenPetitions.org. (2022). Citizen Petition for Faster Market Entry of Biosimilars. Retrieved from https://citizenpetitions.org/citizen-petition-biosimilars

[5] - US FDA. (2023). Patent Expiration Announcements. Retrieved from https://www.fda.gov/drugs/patent-expiration-announcements